JENSCARE-B (09877) is expected to have an annual total revenue of approximately 1.05 billion to 1.1 billion yuan.

JENSCARE-B (09877) released an announcement stating that for the year ending on December 31, 2025, the group is expected to achieve a revenue of approximately 90 to 92 million yuan, with other income and gains totaling approximately 15 to 18 million yuan, for a total of approximately 105 to 110 million yuan. The group's first commercial year has seen significant revenue, mainly attributed to the following factors during the reporting period: 1. The group's Ken-Valve transcatheter aortic valve system achieved stable revenue in its first year of commercialization. Ken-Valve can be used for aortic valve regurgitation or stenosis, and its product design and operational performance advantages have led to rapid adoption of the procedure in multiple levels of medical institutions. 2. The group's various structural heart intervention products have been implanted in fee-based clinical trials overseas, and their research results and clinical application advantages have received high praise from key opinion leaders and experts across all continents worldwide, meeting the long-unmet clinical needs of the global structural heart disease market. In 2026, the group will continue to drive the development of multiple product pipelines and deepen its internationalization strategy to achieve high-speed revenue growth; it will also continuously improve management efficiency and reduce operational costs in production, supply chain, marketing, and operations management, in order to achieve long-term strategic development goals.